Foveolar hyperplasia at the gastric cardia: prevalence and associations

M Voutilainen, M Juhola, M Färkkilä, P Sipponen

Aims: In the gastric antrum and body, foveolar hyperplasia is a feature of reactive gastritis resulting from—for example, duodenogastric bile reflux and the use of non-steroidal anti-inflammatory drugs (NSAIDs). The aim of this study was to examine the occurrence and clinical relevance of gastric cardiac foveolar hyperplasia.

Methods: The study population was drawn from a consecutive series of 1698 patients who had undergone upper gastrointestinal endoscopy. Only cases without chronic gastritis or Barrett’s oesophagus were included. The final study population consisted of 307 patients.

Results: Foveolar hyperplasia was seen in the gastric cardiac mucosa in 31 (10%) patients with histologically normal stomach mucosa, but none had endoscopically noticeable hyperplastic polyps. Compared with patients without gastric cardiac hyperplasia, those with hyperplasia more often had chronic inflammation and complete intestinal metaplasia in the junctional biopsies (48% vs 77% and 9% vs 26%, respectively). Logistic regression analysis revealed that chronic cardiac inflammation (odds ratio (OR), 3.2; 95% confidence interval (CI), 1.3 to 7.8) and intestinal metaplasia of the complete type (OR, 2.8; 95% CI, 1.1 to 7.1) were independent risk factors for cardiac foveolar hyperplasia. In univariate analysis, endoscopic erosive oesophagitis (endoscopy positive gastro-oesophageal reflux disease) and the use of NSAIDs were not related to the presence of foveolar hyperplasia.

Conclusions: Foveolar hyperplasia in the gastric cardiac mucosa occurs in patients with histologically normal non-gastritic stomachs and may develop as a consequence of chronic inflammation limited to the gastro-oesophageal junction (“junctitis”). It is not associated directly with endoscopy positive gastro-oesophageal reflux disease or the use of NSAIDs.

METHODS

Our study population was drawn from 1698 consecutive patients referred for upper gastrointestinal endoscopy as a result of dyspepsia or GORD symptoms. A more detailed description of the study population has been published elsewhere. Those with chronic gastritis of any type, previous Helicobacter pylori eradication treatment, gastric surgery, or Barrett’s oesophagus were excluded. When only cases with adequate biopsy specimens from the gastric antrum, corpus, and cardia were included, the final study population consisted of 307 patients.

The demographic, clinical, and endoscopic data were collected via structured questionnaires from the general practitioners referring the patients for endoscopy, and the doctors performing upper gastrointestinal endoscopies. At endoscopy, the proximal margin of gastric folds was identified as the junction between the oesophagus and stomach. The normal squamocolumnar junction, or Z-line, is coincident with the oesophagogastric junction. The presence of one or more mucosal breaks (erosions or ulcerations) in the distal oesophagus was considered diagnostic for endoscopic erosive oesophagitis (endoscopy positive GORD). Biopsy specimens were obtained from just distal to or across the normal appearing Z-line, from gastric antrum and body (two biopsy specimens from each site).

Biopsy specimens were stained with haematoxylin and eosin, alcian blue periodic acid Schiff pH 2.5 (AB-PAS), and modified Giemsa. Only cases with histologically typical gastric erosive oesophagitis (endoscopy positive GORD).

Abbreviations: AB-PAS, alcian blue periodic acid Schiff; CI, confidence interval; GORD, gastro-oesophageal reflux disease; NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio
Our study population consisted of 307 patients, with a mean age of 53 years (95% confidence interval (CI), 51 to 55) and a male to female ratio of 1:1.8. A total of 31 (10%) patients had gastric foveolar hyperplasia of the cardiac mucosa on histological examination. The presence of hyperplasia was significantly associated with chronic inflammation and intestinal metaplasia of the complete type, whereas endoscopic erosive oesophagitis or the use of NSAIDs showed no association with hyperplasia (table 1). In logistic regression analysis, the presence of foveolar hyperplasia was significantly associated with chronic inflammation (odds ratio (OR), 3.2; 95% CI, 1.3 to 7.8) and intestinal metaplasia of the complete type (OR, 2.8; 95% CI, 1.1 to 7.1) in the cardiac mucosa. In multivariate analysis, gastric cardiac hyperplasia was not associated with either age, sex, or intestinal metaplasia of the incomplete type at the gastro-oesophageal junction.

Nine patients (3%) had a hamartomatous polyp in the gastric body, but no polyps of any type were observed in the gastric cardia or in the gastric antrum. The presence of hamartomatous cystic polyps in the gastric corpus was not associated with cardiac foveolar hyperplasia: one patient (3%) with cardiac foveolar hyperplasia and eight patients (3%) without had hamartomatous polyps in the gastric body.

**DISCUSSION**

Foveolar hyperplasia in the gastric cardiac mucosa and hyperplastic polyps could theoretically be associated with GORD. We excluded those patients with chronic gastritis from our study, and limited the analysis to patients with normal, non-gastritic gastric mucosa. This was done because chronic inflammation at the gastro-oesophageal junction in the cardiac cardia is related to *H pylori* infection in most cases and is, in fact, just an extension of gastritis into the gastric cardia. Therefore, in subjects with *H pylori* associated gastritis, possible cardia specific lesions are intermixed with those related to gastritis. In addition, we only investigated foveolar hyperplasia, not all morphological alterations of classic reactive or chemical gastritis. This was because gastric cardiac inflammation is a very common finding, and not all criteria of reactive gastritis may be applicable to cardiac mucosa.

Our study revealed that cardiac specific foveolar hyperplasia is not an uncommon finding, having a prevalence of 10%, and that it is related to chronic inflammation in the gastric cardia. This frequency is somewhat lower than that found by El-Zimaity et al, who reported a 30% prevalence of cardiac foveolar hyperplasia. In their study, *H pylori* positive patients were included, which certainly affected their results. An even higher prevalence of 77% of foveolar hyperplasia (*H pylori* positive cases included) has also been reported. In our study, foveolar hyperplasia was examined by five pathologists and this may have resulted in variations in the scoring of hyperplasia and may have reduced the reproducibility of the results.

“We found no significant association between gastric cardiac foveolar hyperplasia and endoscopic positive gastro-oesophageal reflux disease”

Noxious agents other than *H pylori* (bile, NSAIDs) induce reactive changes in the gastric mucosa, although results vary

---

Table 1  Results of the comparison between the gastric cardiac hyperplasia group and those without cardiac hyperplasia

<table>
<thead>
<tr>
<th></th>
<th>Hyperplasia (n=31)</th>
<th>No hyperplasia (n=276)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years, 95% CI)</td>
<td>55 (49 to 60)</td>
<td>53 (51 to 55)</td>
</tr>
<tr>
<td>Male : female ratio</td>
<td>1 : 1.2</td>
<td>1 : 1.8</td>
</tr>
<tr>
<td>NSAID use</td>
<td>19%</td>
<td>19%</td>
</tr>
<tr>
<td>Cardia incomplete IM</td>
<td>13%</td>
<td>7%</td>
</tr>
<tr>
<td>Cardia complete IM</td>
<td>26%</td>
<td>9%**</td>
</tr>
<tr>
<td>Carditis</td>
<td>77%</td>
<td>48%**</td>
</tr>
<tr>
<td>Endoscopy positive GORD</td>
<td>19%</td>
<td>14%</td>
</tr>
</tbody>
</table>

**p < 0.01.**

CI, confidence interval; GORD, gastro-oesophageal reflux disease; IM, intestinal metaplasia; NSAID, non-steroidal anti-inflammatory drug.
Take home messages

- Foveolar hyperplasia in the gastric cardiac mucosa is found in patients with histologically normal non-gastric stomachs and may develop as a consequence of chronic inflammation limited to the gastro-oesophageal junction ("junctitis")
- Foveolar hyperplasia in the gastric cardiac mucosa is not associated directly with endoscopy positive gastro-oesophageal reflux disease or the use of non-steroidal anti-inflammatory drugs

ACKNOWLEDGEMENTS

In addition to the authors, the following investigators participated in the present study: I. Ahlskog-Muraja, T. Antikainen, S. Antila, J. Anttinen, M. Hallikas, K-P. Hamalainen, H. Janhonen, M. Kairaluoma, K. Karjalainen, P. Kauranen, M. Kolu, H. Korhonen, J. Korhonen, R. Koskela, R. Krees, J. Kuunamo, V. Kärjä, P. Laaksonen, M. Lautkkanen, R. Liisanantti, M. Lohman, T. Mäntynen, K. Nuorva, A. Palmu, U. Palmu, M. Pellinen, P. Särkkä, H. Selänne, T. Tervo, M. Udd, and J. Viinikka. M. Voutilainen has received research funding from Jyväskylä Central Hospital. A part of this study was presented in poster form and awarded Poster of Distinction prize during the 8th United European Gastroenterology Week, Brussels, 2000.

REFERENCES


Authors’ affiliations

M. Voutilainen, M. Juola, Department of Medicine and Pathology, Jyväskylä Central Hospital, FIN-40620 Jyväskylä, Finland.

M. Färkkila, Department of Medicine, Helsinki University Hospital, FIN-00029 Helsinki, Finland.

P. Sipponen, Department of Pathology, Jorvi Hospital, FIN-02740 Espoo, Finland.

and are conflicting.39 Because the exposure of the gastric cardia to acid must be a frequent, perhaps normal phenomenon,21 which is increased in reflux disease, we wanted to examine whether GORD would induce foveolar hyperplasia at the cardiac mucosa. We found no significant association between gastric cardiac foveolar hyperplasia and endoscopy positive GORD, a result which agrees with that reported by El-Zimaity et al.16 However, endoscopy positive GORD comprises less than half of all GORD cases and a closer study of the associations of cardiac foveolar hyperplasia with non-erosive GORD determined by 24 hour pH monitoring is needed. Our results may also be biased as a result of the exclusion of most of the original study population from our analysis. We excluded patients with Barrett’s oesophagus, because most of them underwent endoscopy as part of a surveillance programme and their inclusion in our present study might have biased our results.

However, chronic cardiac inflammation, which reportedly is associated with GORD,12 13 22 was an independent risk factor for cardiac foveolar hyperplasia. This finding suggests that foveolar hyperplasia may at least indirectly be related to GORD. We suggest that— analogous to H pylori induced foveolar hyperplasia—chronic inflammation at the gastric cardia may induce interleukin production, leading to the development of foveolar hyperplasia in some cases.

Foveolar hyperplasia may be the precursor lesion for hyperplastic polyps, although this view is not uniformly accepted.25 We found no gastric cardiac hyperplastic polyps, but a cross sectional study does not exclude the possibility that foveolar hyperplasia may in time progress to hyperplastic polyps. Hyperplastic cardiac polyps reportedly occur, although most are seen in the gastric corpus or antrum.24 However, hyperplastic nodules at the gastro-oesophageal junction may progress to high grade dysplasia.25 The risk of gastric cardiac hyperplastic changes developing into dysplasia and carcinoma is obviously very low.

In conclusion, foveolar hyperplasia of the gastric cardiac mucosa occurs in subjects with normal, non-gastric stomachs, and is closely related to chronic inflammation of the gastric cardiac mucosa. Gastric cardiac foveolar hyperplasia does not seem to be a direct objective marker for GORD.

Foveolar hyperplasia at the gastric cardia: prevalence and associations

M Voutilainen, M Juhola, M Färkkilä and P Sipponen

doi: